SLC5A2 and diabetic ketoacidosis: However, the experience in using GLP-1 analogues in people with T1DM remains limited [23, 24]; while the use and licensing of SGLT2 inhibitors in individuals with T1DM have been restricted due to the increased risk of diabetic ketoacidosis [23, 24].